` BPMC (Blueprint Medicines Corp) vs S&P 500 Comparison - Alpha Spread

BPMC
vs
S&P 500

Over the past 12 months, BPMC has outperformed S&P 500, delivering a return of 23% compared to the S&P 500's 9% growth.

Stocks Performance
BPMC vs S&P 500

Loading
BPMC
S&P 500
Add Stock

Performance Gap
BPMC vs S&P 500

Performance Gap Between BPMC and GSPC
HIDDEN
Show

Performance By Year
BPMC vs S&P 500

Loading
BPMC
S&P 500
Add Stock

Competitors Performance
Blueprint Medicines Corp vs Peers

S&P 500
BPMC
ABBV
AMGN
GILD
VRTX
Add Stock

Blueprint Medicines Corp
Glance View

Economic Moat
Narrow
Market Cap
8.3B USD
Industry
Biotechnology

In the demanding world of biotechnology, Blueprint Medicines Corp stands out as an influential player, steering the course of precision therapy through innovation. Founded by a team of forward-thinking scientists, the company is deeply entrenched in the pursuit of novel treatments targeting rare genetic diseases and cancers driven by specific genomic alterations. Leveraging its proprietary compound library and a research-centric approach, Blueprint Medicines develops small-molecule kinase inhibitors designed to selectively modulate growth and survival signals in cells. The company’s strategic focus on genomically defined indications allows it to address unmet medical needs, thereby creating substantial value through focused research and rapid clinical advancements. The financial backbone of Blueprint Medicines is built upon a well-rounded strategy encompassing both in-house drug development and strategic collaborations. As the company shepherds its proprietary drugs through the rigorous phases of clinical trials, it also engages in valuable partnerships with pharmaceutical giants to bolster its research capabilities and market reach. With approval and commercialization of therapies like Ayvakit for certain forms of gastrointestinal stromal tumors, Blueprint Medicines generates substantial revenue. These gains are further compounded by milestone payments and royalties from collaborations, all while maintaining a robust pipeline to ensure continued innovation and future income streams. In this way, Blueprint marries scientific rigor with strategic acumen, carving out a sustainable and impactful presence in the biopharmaceutical landscape.

BPMC Intrinsic Value
HIDDEN
Show
Back to Top